Shares of Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) have been assigned a consensus recommendation of “Buy” from the ten analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $30.25.
RCUS has been the subject of a number of recent analyst reports. Morgan Stanley reduced their price objective on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Bank of America cut their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, February 19th. Finally, HC Wainwright upgraded Arcus Biosciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $18.00 to $24.00 in a research report on Wednesday, February 26th.
Get Our Latest Stock Report on Arcus Biosciences
Arcus Biosciences Stock Performance
Arcus Biosciences (NYSE:RCUS – Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) EPS for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.14. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company had revenue of $36.00 million for the quarter, compared to analyst estimates of $29.38 million. On average, equities analysts forecast that Arcus Biosciences will post -3.15 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, CFO Robert C. Goeltz II sold 3,594 shares of the company’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the transaction, the chief financial officer now owns 60,138 shares in the company, valued at $902,070. The trade was a 5.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Yasunori Kaneko acquired 20,000 shares of Arcus Biosciences stock in a transaction that occurred on Thursday, February 27th. The stock was acquired at an average price of $10.06 per share, with a total value of $201,200.00. Following the completion of the acquisition, the director now directly owns 28,400 shares in the company, valued at $285,704. This represents a 238.10 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in RCUS. Gilead Sciences Inc. purchased a new position in shares of Arcus Biosciences during the fourth quarter valued at $447,610,000. Boxer Capital Management LLC bought a new stake in shares of Arcus Biosciences in the 4th quarter valued at about $23,857,000. Braidwell LP bought a new stake in shares of Arcus Biosciences in the 4th quarter valued at about $11,943,000. Millennium Management LLC lifted its position in shares of Arcus Biosciences by 277.1% in the 4th quarter. Millennium Management LLC now owns 924,369 shares of the company’s stock worth $13,764,000 after purchasing an additional 679,267 shares during the period. Finally, Parkman Healthcare Partners LLC increased its holdings in Arcus Biosciences by 146.9% during the third quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company’s stock valued at $15,684,000 after buying an additional 610,219 shares during the period. Institutional investors own 92.89% of the company’s stock.
About Arcus Biosciences
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Featured Articles
- Five stocks we like better than Arcus Biosciences
- Conference Calls and Individual Investors
- Can TikTok Stock Picks Really Make You Rich?
- Market Cap Calculator: How to Calculate Market Cap
- The “Quality” Rotation: Back to Basics Investing
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.